The discovery of driver mutations in myeloproliferative neoplasms has significantly contributed to the management of patients with essential thrombocythaemia (ET). High-quality evidence has started to pave the way for targeted therapy. The review by Ferrer-Marín et al. further advances this discussion, highlighting how molecular profiling, including non-driver gene mutations, is set to revolutionize personalized treatment approaches for ET patients. Commentary on: Ferrer-Marín et al. Essential thrombocythemia: a contemporary approach with new drugs on the horizon. Br J Haematol 2024;204:1605-1616.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.19437 | DOI Listing |
Publication Analysis
Top Keywords
essential thrombocythaemia
8
ferrer-marín et al
8
sailing deceptive
4
deceptive calm
4
calm navigating
4
navigating undercurrents
4
undercurrents essential
4
thrombocythaemia discovery
4
discovery driver
4
driver mutations
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!